blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1200097

EP1200097 - METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION [Right-click to bookmark this link]
Former [2002/18]METHOD FOR CONTROLLING THE FIDELITY AND THE EXECUTION OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION
[2014/02]
StatusNo opposition filed within time limit
Status updated on  14.11.2014
Database last updated on 22.01.2025
Most recent event   Tooltip08.07.2016Lapse of the patent in a contracting state
New state(s): BE		published on 10.08.2016  [2016/32]
Applicant(s)For all designated states
Vigilent Technologies
Les Grands Pains
38160 Chevrieres / FR
[2014/01]
Former [2005/32]For all designated states
Vigilent Technologies
26 rue de Cernay
91470 Les Molières / FR
Former [2002/18]For all designated states
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
3, rue Michel Ange
75794 Paris Cedex 16 / FR
Inventor(s)01 / DERRIEN, Valérie
52, rue du Moulin Vert
F-75014 Paris / FR
02 / REISS, Claude
26, rue de Cernay
F-91470 Les Molières / FR
 [2002/18]
Representative(s)Catherine, Alain, et al
Cabinet HARLE et PHELIP
14-16, Rue Ballu
75009 Paris / FR
[N/P]
Former [2014/02]Catherine, Alain, et al
Cabinet HARLE et PHELIP 14-16, rue Ballu
75009 Paris / FR
Former [2005/29]Catherine, Alain, et al
Cabinet Harlé & Phélip 7, rue de Madrid
75008 Paris / FR
Former [2002/18]Warcoin, Jacques, et al
Cabinet Régimbeau 20, rue de Chazelles
75847 Paris cedex 17 / FR
Application number, filing date00925427.710.05.2000
[2002/18]
WO2000FR01260
Priority number, dateFR1999000590510.05.1999         Original published format: FR 9905905
[2002/18]
Filing languageFR
Procedural languageFR
PublicationType: A2 Application without search report
No.:WO0067698
Date:16.11.2000
Language:FR
[2000/46]
Type: A2 Application without search report 
No.:EP1200097
Date:02.05.2002
Language:FR
The application published by WIPO in one of the EPO official languages on 16.11.2000 takes the place of the publication of the European patent application.
[2002/18]
Type: B1 Patent specification 
No.:EP1200097
Date:08.01.2014
Language:FR
[2014/02]
Search report(s)International search report - published on:EP14.02.2002
ClassificationIPC:A61K31/70, A61K31/505, A61K31/55, A61K31/165, A61K31/495, A61K31/66, A61K31/47
[2002/18]
CPC:
A61K31/662 (EP,US); A61K31/165 (EP,US); A61K31/4709 (EP,US);
A61K31/496 (EP,US); A61K31/506 (EP,US); A61K31/519 (EP,US);
A61K31/551 (EP,US); A61K31/5513 (EP,US); A61K31/706 (EP,US);
A61K31/7064 (EP,US); A61K31/7076 (EP,US); A61K31/708 (EP,US);
A61P31/14 (EP); A61P31/18 (EP); A61P35/02 (EP);
A61P43/00 (EP) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2002/18]
TitleGerman:METHODE ZUR KONTROLLE DER TREUE UND DER PROZESSIVITÄT DER REVERSTRANSCRIPTASE DURCH INKORPORIERUNG UND POLYMERISIERUNG VON NUCLEOTIDANALOGEN DIE ALS SUBSTRATE DER REVERSTRANSCRIPTIONSREAKTION AKZEPTIERT WERDEN OHNE DIE ELONGIERUNG ZU BLOCKIEREN[2014/02]
English:METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION[2014/02]
French:METHODE POUR CONTROLER LA FIDELITE ET LA PROCESSIVITE DE LA REVERSE TRANSCRIPTASE PAR INCORPORATION ET POLYMERISATION D'ANALOGUES DE NUCLEOTIDES ACCEPTES COMME SUBSTRATS DE LA REACTION DE REVERSE TRANSCRIPTION SANS BLOQUER SON ELONGATION[2002/18]
Former [2002/18]METHODE ZUR KONTROLLE DER TREUE UND DES PROZESSABLAUFS DER REVERSTRANSCRIPTASE DURCH INKORPORIERUNG UND POLYMERISIERUNG VON NUCLEOTIDANALOGEN DIE ALS SUBSTRATE DER REVERSTRANSCRIPTIONSREAKTION AKZEPTIERT WERDEN OHNE DIE ELONGIERUNG ZU BLOCKIEREN
Former [2002/18]METHOD FOR CONTROLLING THE FIDELITY AND THE EXECUTION OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION
Entry into regional phase26.11.2001National basic fee paid 
26.11.2001Designation fee(s) paid 
26.11.2001Examination fee paid 
Examination procedure04.12.2000Request for preliminary examination filed
International Preliminary Examining Authority: EP
26.11.2001Examination requested  [2002/18]
30.04.2004Despatch of a communication from the examining division (Time limit: M06)
15.12.2004Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
24.02.2005Reply to a communication from the examining division
25.02.2008Despatch of a communication from the examining division (Time limit: M06)
07.08.2008Reply to a communication from the examining division
23.03.2011Despatch of a communication from the examining division (Time limit: M06)
12.07.2011Reply to a communication from the examining division
07.02.2013Despatch of a communication from the examining division (Time limit: M02)
09.04.2013Reply to a communication from the examining division
25.07.2013Communication of intention to grant the patent
08.11.2013Fee for grant paid
08.11.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.04.2004
Opposition(s)09.10.2014No opposition filed within time limit [2014/51]
Request for further processing for:24.02.2005Request for further processing filed
24.02.2005Full payment received (date of receipt of payment)
Request granted
09.03.2005Decision despatched
Fees paidRenewal fee
28.05.2002Renewal fee patent year 03
26.05.2003Renewal fee patent year 04
26.05.2004Renewal fee patent year 05
19.05.2005Renewal fee patent year 06
19.05.2006Renewal fee patent year 07
19.05.2007Renewal fee patent year 08
23.05.2008Renewal fee patent year 09
20.05.2009Renewal fee patent year 10
22.05.2010Renewal fee patent year 11
24.05.2011Renewal fee patent year 12
19.03.2012Renewal fee patent year 13
21.05.2013Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
IT08.01.2014
MC08.01.2014
NL08.01.2014
SE08.01.2014
GR09.04.2014
PT08.05.2014
GB10.05.2014
IE10.05.2014
LU10.05.2014
BE31.05.2014
CH31.05.2014
LI31.05.2014
[2016/32]
Former [2016/29]AT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
IT08.01.2014
MC08.01.2014
NL08.01.2014
SE08.01.2014
GR09.04.2014
PT08.05.2014
GB10.05.2014
IE10.05.2014
LU10.05.2014
CH31.05.2014
LI31.05.2014
Former [2016/28]AT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
MC08.01.2014
NL08.01.2014
SE08.01.2014
GR09.04.2014
PT08.05.2014
GB10.05.2014
IE10.05.2014
LU10.05.2014
CH31.05.2014
LI31.05.2014
Former [2015/24]AT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
MC08.01.2014
NL08.01.2014
SE08.01.2014
PT08.05.2014
GB10.05.2014
IE10.05.2014
LU10.05.2014
CH31.05.2014
LI31.05.2014
Former [2015/21]AT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
MC08.01.2014
NL08.01.2014
SE08.01.2014
PT08.05.2014
IE10.05.2014
LU10.05.2014
CH31.05.2014
LI31.05.2014
Former [2015/09]AT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
MC08.01.2014
NL08.01.2014
SE08.01.2014
PT08.05.2014
LU10.05.2014
CH31.05.2014
LI31.05.2014
Former [2015/08]AT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
NL08.01.2014
SE08.01.2014
PT08.05.2014
LU10.05.2014
CH31.05.2014
LI31.05.2014
Former [2015/04]AT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
NL08.01.2014
SE08.01.2014
PT08.05.2014
LU10.05.2014
Former [2014/48]AT08.01.2014
CY08.01.2014
DK08.01.2014
ES08.01.2014
FI08.01.2014
NL08.01.2014
SE08.01.2014
PT08.05.2014
Former [2014/39]AT08.01.2014
CY08.01.2014
ES08.01.2014
FI08.01.2014
NL08.01.2014
SE08.01.2014
PT08.05.2014
Former [2014/37]AT08.01.2014
CY08.01.2014
ES08.01.2014
FI08.01.2014
SE08.01.2014
PT08.05.2014
Cited inInternational search[X]WO9640166  (HOSTETLER KARL Y [US]) [X] 18,24 * example 8 *
 [X]  - MARTINEZ M A ET AL, "REVERSE TRANCRIPTASE AND SUBSTRATE DEPENDENCE OF THE RNA HYPERMUTAGENESIS REACTION", NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, (1995), vol. 23, no. 14, ISSN 0305-1048, pages 2573 - 2578, XP000876548 [X] 1-17,21 * the whole document *
 [X]  - MCINTOSH, EVAN M. (1) ET AL, "HIV and human endogenous retroviruses: A hypothesis with therapeutic implications.", ACTA BIOCHIMICA POLONICA, (1997) VOL. 43, NO. 4, PP. 583-592., XP000878787 [X] 1-17,21 * abstract * * page 589, column 2, paragraph 2 - page 590, column 1, paragraph 1 *
 [X]  - TONG, WENJING ET AL, "Nucleotide-Induced Stable Complex Formation by HIV -1 Reverse Transcriptase", BIOCHEMISTRY (1997), 36(19), 5749-5757, XP002131945 [X] 1-17,21 * abstract * * page 5749, column 1, paragraph 1 - page 5750, column 1, paragraph 3; tables 2,3 * * page 5753, column 1, paragraph 3 - page 5756, column 1, paragraph 4 *

DOI:   http://dx.doi.org/10.1021/bi962410z
 [X]  - OSTRANDER, MICHAEL ET AL, "Properties of herpes simplex virus type 1 and type 2 DNA polymerase", BIOCHIM. BIOPHYS. ACTA (1980), 609(2), 232-45, XP001014122 [X] 1-17,21 * abstract *
 [X]  - LOAKES D ET AL, "ANTIVIRAL ACTIVITY OF BICYCLIC PYRIMIDINE NUCLEOSIDES", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY,GB,BLACKWELL SCIENTIFIC PUBL., LONDON, (1995), vol. 6, no. 6, ISSN 0956-3202, pages 371 - 378, XP000671407 [X] 1-17,19-22,24-27 * the whole document *
 [X]  - HILL, F. ET AL., "Comparative mutagenicities of N6-methoxy-2,6-diaminopurine and N6-methoxyaminopurine 2'-deoxyribonucleosides and their 5'-triphosphates", NUCLEIC ACIDS RES., vol. 26, no. 5, pages 1144 - 1149, XP002172901 [X] 1-7,11-17,19-21,24,25 * abstract * * page 1144, column 1, paragraph 1 - column 2, paragraph 2; figure 1 * * page 1146, column 1, paragraph 3 - page 1148, column 1, paragraph 1; table 1 *

DOI:   http://dx.doi.org/10.1093/nar/26.5.1144
 [X]  - KOWALZICK L ET AL, "DIFFERENTIAL INCORPORATION OF THYMIDYLATE ANALOGS INTO DNA BY DNA POLYMERASE ALPHA AND BY DNA POLYMERASES SPECIFIED BY 2 HERPES SIMPLEX VIRUSES.", J GEN VIROL, (1982) 62 (PART 1), 29-38., XP001014120 [X] 1-19,22,24-26 * the whole document *
 [X]  - DE CLERCQ, ERIK, "Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?", INT. J. ANTIMICROB. AGENTS (1997), 9(1), 21-36, XP000878561 [X] 1 * abstract * * page 30, column 1, paragraph 4 - page 33, column 2, paragraph 3 * * tables 1-9 *

DOI:   http://dx.doi.org/10.1016/S0924-8579(97)00031-9
 [X]  - MORRIS-JONES, STEPHEN ET AL, "Antiretroviral therapies in HIV-1 infection", EXPERT OPIN. INVEST. DRUGS (1997), 6(8), 1049-1061, XP002131942 [X] 1 * page 1050, column 1, paragraph 4 - page 1058, column 2, line 1; tables 1-5B *

DOI:   http://dx.doi.org/10.1517/13543784.6.8.1049
 [X]  - PATICK, A. K. ET AL, "Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro", ANTIMICROB. AGENTS CHEMOTHER. (1997), 41(10), 2159-2164, XP002131943 [X] 1 * abstract *
 [X]  - DEBYSER, Z. ET AL, "Antiviral therapy for HIV infection", EOS--RIV. IMMUNOL. IMMUNOFARMACOL. (1996), 16(2), 48-52, XP002131944 [X] 1 * page 51, column 1, paragraph 2 - column 2, paragraph 1 *
 [X]  - CLERCQ DE E ET AL, "KNOCKING OUT HUMAN IMMUNODEFICIENCY VIRUS THROUGH NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS USED AS SINGLE AGENTS OR IN COMBINATIONS: A PARADIGM FOR THE CURE OF AIDS?", FARMACO,IT,SOCIETA CHIMICA ITALIANA, PAVIA, (19951101), vol. 50, no. 11, ISSN 0014-827X, pages 735 - 747, XP000579600 [X] 1 * abstract * * page 742, column 2, paragraph 2 - page 745, column 2, paragraph 1 *
 [X]  - GRANIER F. ET AL, "[HIV infections: Contribution of antiretroviral combinations ]. INFECTIONS A VIH: L'APPORT DES COMBINAISONS ANTIRETROVIRALES.", PRESSE MEDICALE, (4 APR 1998) 27/13 (622-623)., XP002131947 [X] 1-9,11-28 * the whole document *
ExaminationWO9721452
 WO9418979
 WO9628162
    - BERGMAN A M ET AL, "BIOLOGICAL ACTIVITY OF 1-DEAZAPURINE NUCLEOSIDES: ROLE OF DEOXYCYTIDINE KINASE?", NUCLEOSIDES & NUCLEOTIDES, MARCEL DEKKER, INC, US, (19990401), vol. 18, no. 4-5, ISSN 0732-8311, pages 897 - 898, XP002997965
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.